TearRestore Announces Positive Clinical Trial Results for Patients with Dry Eye Disease
TearRestore announced positive toptine results of a study conducted by the University of Colorado titled, “The Effect of Warm Compress Therapy on Dry Eye Disease,” using the TearRestore Thermal Mask.
Study assessments were performed before a single 10-minute session of wearing the TearRestore Mask and then study assessments were repeated after the 10-minute single session had been completed. Additionally, subjects extended the use of the TearRestore Mask at home for a period of 28 to 60 days for a 10-minute time period one time per day and recorded the use in a diary.
The trial collected data from a population of 22 eyes (age 18-89) in patients diagnosed with meibomian gland dysfunction (MGD) over 28–60 days. The study revealed:
- A 90% increase in tear break-up time
- A 51% reduction in dry eye symptoms
- A 40% increase in functional meibomian glands
“We are thrilled with the results of the University of Colorado study. They further confirm that the TearRestore Mask offers patients an unparalleled experience by providing sustained heat and the ability to see throughout the treatment, which will improve efficacy and compliance,” Ken DauSchmidt, co-founder and CEO of TearRestore, said in a company news release. “No other thermal mask can provide this level of effectiveness.”
“By showing that the mask is effective in altering Meibomian gland secretions at a single visit, the study proves that this novel treatment could potentially offer the millions of patients suffering from MGD a more convenient and effective way to treat the condition,” Mr. DauSchmidt said.
The TearRestore Thermal Mask is available at TearRestore.com and Amazon. More information on the study can be found here.